ARK Research: “Multiomics Could Unlock a New Era of Healthcare” (Big Ideas 2026)

[!warning] Conflict of Interest ARK Invest is an active fund manager with major positions in genomics and multiomics companies. This is a promotional teaser for the multiomics section of Big Ideas 2026, designed to attract capital into ARK’s genomics funds.

Assessment

Another promotional teaser for Big Ideas 2026, this time focused on the multiomics thesis. Thin on standalone content — primarily a framing piece driving downloads of the full report.

Key Claims

• Sequencing costs could decline ~10x by 2030 while molecular test data volumes increase 10x
• This creates a flywheel: more biological data improves AI models, which improve diagnostics/therapies, which generate more data
• By 2030, roughly one-third of FDA-approved diagnostics and medical devices could be AI-powered
• Drug development timelines could shrink and success rates could rise

RDCO Mapping

The data flywheel concept (cheaper sequencing -> more data -> better AI -> better outcomes -> more data) is a useful framework for evaluating genomics investments. The 10x cost decline / 10x data volume projection by 2030 is worth tracking against reality. Full Big Ideas 2026 PDF likely contains more actionable data points.